Company Overview
Company Type: Public Company
Website: core1labs.com
Number of Employees: -
Ticker: COOL (CNSX)
Year Founded: 2010


Business Description
Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.5
Market Capitalization
16.3
TEV/Total Revenue
34.6x
EBITDA
(7.7)
Total Enterprise Value
15.9
TEV/EBITDA
NM
EBIT
(7.8)
Cash & ST Invst.
0.7
P/Diluted EPS Before Extra
NM
Net Income
(16.0)
Total Debt
0.3
Price/Tang BV
37.3x
Capital Expenditure
0.0
Total Assets
8.1
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Shacker, Joel 
CEO & Director
Eckenweiler, Brad Paul
Founder & Advisor
Balderson, Geoffrey 
CFO, Secretary & Director
Burian, Jan 
Chief Technical Officer
Ferro, Santiago 
Chief Medical Officer & Director
Matthews, Elizabeth 
Head of Scientific & Regulatory Affairs

Key Board Members
Name
Title
Shacker, Joel 
CEO & Director
Balderson, Geoffrey 
CFO, Secretary & Director
Ferro, Santiago 
Chief Medical Officer & Director
Morris, Patrick C.T.
Independent Director
Polonenko, Dan 
Member of Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
595 Burrard Street Suite 3123 Three Bentall Centre PO Box 49139 | Vancouver, BC | V7X 1J1 | Canada

Current and Pending Investors
Right Season Investments Corp. (TSXV:LITT)

Prior Investors
Plant-Based Investment Corp. (OTCPK:CWWB.F)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.35
Market Cap (mm)
16.3
Open
 0.35
Shares Out. (mm)
46.6
Previous Close
 0.35
Float %
98.7%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.35/ 0.32
Diluted EPS Excl. Extra Items
(0.49)
52 wk High/Low
 1.14/ 0.32
P/Diluted EPS Before Extra
NM
Volume (mm)
0.09
Avg 3M Dly Vlm (mm)
0.10
Beta 5Y
2.12


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:COOL - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
GMP Drug Inc.
GMP Drug Inc. operates as an arms-length privately held company that operates through a Good Manufacturing Practices (“GMP”) facility. The company was incorporated in 2020 and is based in Victoria, Canada. As of January 13, 2023, GMP Drug Inc. operates as a subsidiary of Core One Labs Inc.

United States and Canada
Pharmaceuticals
-
-
-
Awakened Biosciences Inc.
Awakened Biosciences Inc., a psychedelics research and technology company, engages in the research and development, production, and manufacture of psilocybin-based prodrugs. It develops technologies for the production of synthetic psilocybin, the synthetic production of psilocybin and psilocin analogues, and for the manufacturing of various no-psychoactive psilocybin-based prodrugs. The company is based in the United States. As of February 10, 2022, Awakened Biosciences Inc. operates as a subsidiary of Core One Labs Inc.

United States and Canada
Pharmaceuticals
-
-
-
New Path Laboratories Inc.
New Path Laboratories Inc. engages in the development and licensing of natural health products and dietary supplements. The company is based in Vancouver, Canada. As of December 23, 2021, New Path Laboratories Inc. operates as a subsidiary of Core One Labs Inc.

United States and Canada
Personal Care Products
-
-
-
Frontier Mycology Corp.
Frontier Mycology Corp. operates an online platform that provides news and media coverage, financial analysis, and relevant research on both functional and psychedelic mushrooms. The company was incorporated in 2021 and is based in Vancouver, Canada. As of August 17, 2021, Frontier Mycology Corp. operates as a subsidiary of Core One Labs Inc.

United States and Canada
Interactive Media and Services
-
-
-
Akome Biotech Ltd.
As of May 4, 2021, Akome Biotech Ltd. operates as a subsidiary of Core One Labs Inc.

United States and Canada
Pharmaceuticals
-
-
-
Bluejay Mental Health Group Inc.
Bluejay Mental Health Group Inc. owns and operates health care clinics that provides alternative health treatments in the form of cannabis prescriptions. The company was founded in 2011 and is based in Langley, Canada. As of March 11, 2021, Bluejay Mental Health Group Inc. operates as a subsidiary of Core One Labs Inc.

United States and Canada
Health Care Facilities
-
-
-
Ketamine Infusion Centers of Texas, LLC
Ketamine Infusion Centers of Texas, LLC owns and operates a wellness clinic for treating treatment-resistant depression and other mental health disorders. The company was incorporated in 2019 and is based in The Woodlands, Texas.

United States and Canada
Health Care Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-11-2023
Sep-18-2023
Private Placement
Target
Core One Labs Inc. (CNSX:COOL)


0.15
Jan-13-2023
Jan-13-2023
Merger/Acquisition
Buyer
GMP Drug Inc.
Core One Labs Inc. (CNSX:COOL)

2.61
Feb-11-2022
Feb-10-2022
Merger/Acquisition
Buyer
Awakened Biosciences Inc.
Core One Labs Inc. (CNSX:COOL)

-
Dec-23-2021
Dec-23-2021
Merger/Acquisition
Buyer
New Path Laboratories Inc.
Core One Labs Inc. (CNSX:COOL)

2.62
Aug-17-2021
Aug-17-2021
Merger/Acquisition
Buyer
Frontier Mycology Corp.
Core One Labs Inc. (CNSX:COOL)

5.94
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-18-2023
Private Placements
Core One Labs Inc. announced that it has received CAD 0.2 million in funding
Sep-11-2023
Private Placements
Core One Labs Inc. announced that it expects to receive CAD 1 million in funding
Aug-04-2023
Product-Related Announcements
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
Jul-28-2023
Product-Related Announcements
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
Jun-27-2023
Product-Related Announcements
Core One Labs Inc. Applauds FDA's Draft Guidance on Clinical Trials for Psychedelic Drugs

Competitors
1933 Industries Inc. (CNSX:TGIF), iAnthus Capital Holdings, Inc. (CNSX:IAN), Vertical Peak Holdings Inc. (CNSX:MJMJ)


Advisors
Most Recent Auditor
Dale Matheson Carr-Hilton LaBonte LLP
Private Placement Advisors
Canaccord Genuity Corp.
Public Offering Advisors
Davidson & Company LLP, McMillan LLP


Most Recent Auditor
Dale Matheson Carr-Hilton


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
MarketLine

Sep 20, 2023 06:01 AM
COOL
Core One Labs Inc
Reports
35
Wright Investors' Service Inc.

May 23, 2023 01:45 AM
COOL
Flow of Funds Report for Core One Labs Inc - prepared by Wright Investors Service
Notes
69
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
May 16, 2023 06:00 PM
COOL
Rating Update for Core One Labs Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Apr 30, 2023 06:00 PM
COOL
Will Core One Labs Inc Deliver Top-Shelf Performance?
Ratings Change*
12
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Mar 27, 2023 06:00 PM
COOL
Rating Update for Core One Labs Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jan 10, 2023 05:00 PM
COOL
Rating Update for Core One Labs Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jan 05, 2023 05:00 PM
COOL
Is Core One Labs Inc Worth a Higher Bid?
Ratings Change*
12
CFRA Equity Research

Jan 03, 2023 12:11 PM
COOL
Core One Labs Inc.
Reports
9
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Apr 11, 2021 06:00 PM
COOL
Rating Update for Core One Labs Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.

Nov 27, 2019 05:00 PM
COOL
Is Core One Labs Inc Still a Bargain?
Ratings Change*
12


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Shacker, Joel 

334,314

0.72

0.1

Aug-11-2023


Ferro, Santiago 

128,654

0.28

0.0

Aug-03-2023


Morris, Patrick C.T.

78,125

0.17

0.0

Jul-04-2023


Balderson, Geoffrey 

49,500

0.11

0.0

Sep-18-2023


Front Row Advisors LLC

0

0.00

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Balderson, Geoffrey 
49,500
12,500

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Shacker, Joel 
334,314
(30,000)
Front Row Advisors LLC
0
(62)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CannaStrips, Consulting Services, Psilocybin Active Pharmaceutical Ingredient (Future), Psychedelic Drugs (Future), Track and Trace Software (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-18-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
Material Change Report
266 KB
Sep-18-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
News Releases
189 KB
Sep-11-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
News Releases
180 KB
Aug-29-2023
Jun-30-2023
Core One Labs Inc. (CNSX:COOL)
SEDAR
Interim Financial Statements
465 KB
Aug-24-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
News Releases
150 KB
Aug-08-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
News Releases
165 KB
Aug-04-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
Material Change Report
190 KB
Aug-03-2023
Mar-31-2023
Core One Labs Inc. (CNSX:COOL)
SEDAR
Annual Financial Statements
686 KB
Aug-03-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
News Releases
131 KB
Aug-02-2023
-
Core One Labs Inc. (CNSX:COOL)
SEDAR
News Releases
180 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Balderson, Geoffrey  (CFO, Secretary & Director)
Sep-18-2023
Common Shares
12,500
-
Other Acquisition
33.78
Multiple
Shacker, Joel  (CEO & Director)
Aug-11-2023
Common Shares
(10,000)
-
Open Market Disposition
(2.90)
Multiple
Shacker, Joel  (CEO & Director)
Aug-08-2023
Common Shares
(40,000)
-
Open Market Disposition
(10.41)
Multiple
Shacker, Joel  (CEO & Director)
Jul-07-2023
Common Shares
10,000
4,029
Open Market Acquisition
2.67
Multiple
Shacker, Joel  (CEO & Director)
Jul-05-2023
Common Shares
10,000
4,039
Open Market Acquisition
2.74
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Shacker, Joel 
CEO & Director
+1 778-735-1000
-
joelshacker@hotmail.com
Balderson, Geoffrey 
CFO, Secretary & Director
(604) 604-0001
-
gbalderson@aleriogold.com
Ferro, Santiago 
Chief Medical Officer & Director
-
-

Morris, Patrick C.T.
Independent Director
604-283-1722
-

Polonenko, Dan 
Member of Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Shacker, Joel 
CEO & Director
+1 778-735-1000
-
joelshacker@hotmail.com
Eckenweiler, Brad Paul
Founder & Advisor
-
-

Balderson, Geoffrey 
CFO, Secretary & Director
(604) 604-0001
-
gbalderson@aleriogold.com
Burian, Jan 
Chief Technical Officer
-
-

Ferro, Santiago 
Chief Medical Officer & Director
-
-

Matthews, Elizabeth 
Head of Scientific & Regulatory Affairs
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
